MX2024004447A - Anticuerpos dirigidos a ccr2. - Google Patents
Anticuerpos dirigidos a ccr2.Info
- Publication number
- MX2024004447A MX2024004447A MX2024004447A MX2024004447A MX2024004447A MX 2024004447 A MX2024004447 A MX 2024004447A MX 2024004447 A MX2024004447 A MX 2024004447A MX 2024004447 A MX2024004447 A MX 2024004447A MX 2024004447 A MX2024004447 A MX 2024004447A
- Authority
- MX
- Mexico
- Prior art keywords
- ccr2
- antibodies
- diseases
- antibodies targeted
- ccl2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21204904 | 2021-10-27 | ||
| PCT/EP2022/079744 WO2023072916A1 (en) | 2021-10-27 | 2022-10-25 | Antibodies targeting ccr2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004447A true MX2024004447A (es) | 2024-05-08 |
Family
ID=78413745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004447A MX2024004447A (es) | 2021-10-27 | 2022-10-25 | Anticuerpos dirigidos a ccr2. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12168692B1 (https=) |
| EP (1) | EP4423131A1 (https=) |
| JP (1) | JP2024540196A (https=) |
| KR (1) | KR20240099211A9 (https=) |
| CN (1) | CN118159562A (https=) |
| AU (1) | AU2022378899A1 (https=) |
| CA (1) | CA3231124A1 (https=) |
| IL (1) | IL311476A (https=) |
| MX (1) | MX2024004447A (https=) |
| WO (1) | WO2023072916A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024245988A1 (en) * | 2023-05-29 | 2024-12-05 | Granite Bio Ag | Antibodies targeting ccr2 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE102006015341A1 (de) | 2006-04-03 | 2007-10-04 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Behandlung von multipler Sklerose und/oder rheumatoider Arthritis |
| JP5685535B2 (ja) | 2008-08-18 | 2015-03-18 | ファイザー インコーポレイティッド | Ｃｃｒ２に対する抗体 |
| HK1208236A1 (en) | 2012-06-22 | 2016-02-26 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ccr2 |
| EP2727944A1 (en) * | 2012-10-30 | 2014-05-07 | Universitätsklinikum Regensburg | Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system |
| WO2016079276A1 (en) | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease |
-
2022
- 2022-10-25 JP JP2024525765A patent/JP2024540196A/ja active Pending
- 2022-10-25 AU AU2022378899A patent/AU2022378899A1/en active Pending
- 2022-10-25 CN CN202280072046.7A patent/CN118159562A/zh active Pending
- 2022-10-25 KR KR1020247013799A patent/KR20240099211A9/ko active Pending
- 2022-10-25 CA CA3231124A patent/CA3231124A1/en active Pending
- 2022-10-25 EP EP22812470.7A patent/EP4423131A1/en active Pending
- 2022-10-25 MX MX2024004447A patent/MX2024004447A/es unknown
- 2022-10-25 WO PCT/EP2022/079744 patent/WO2023072916A1/en not_active Ceased
- 2022-10-25 IL IL311476A patent/IL311476A/en unknown
-
2024
- 2024-08-02 US US18/793,279 patent/US12168692B1/en active Active
- 2024-11-06 US US18/938,749 patent/US20250059288A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240392018A1 (en) | 2024-11-28 |
| AU2022378899A1 (en) | 2024-03-07 |
| KR20240099211A (ko) | 2024-06-28 |
| US12168692B1 (en) | 2024-12-17 |
| CN118159562A (zh) | 2024-06-07 |
| JP2024540196A (ja) | 2024-10-31 |
| WO2023072916A1 (en) | 2023-05-04 |
| KR20240099211A9 (ko) | 2025-12-10 |
| EP4423131A1 (en) | 2024-09-04 |
| CA3231124A1 (en) | 2023-05-04 |
| IL311476A (en) | 2024-05-01 |
| US20250059288A1 (en) | 2025-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
| MX2020006715A (es) | Anticuerpos especificos del heterodimero de cd3-delta/epsilon. | |
| AR092612A1 (es) | Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20, y usos de los mismos | |
| CL2018002383A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmunológicamente activos de los mismos y sus usos. (divisional solicitud 201202433) | |
| ECSP20039728A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos | |
| MX2022003306A (es) | Inmunocitoquina que comprende un complejo de proteina heterodimerico basado en il-15/il-15ra y su uso. | |
| CO2020003165A2 (es) | Anticuerpos de la proteína de muerte celular programada 1 | |
| PE20151893A1 (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular | |
| UY36539A (es) | Proteínas de unión a icos | |
| MX2020013122A (es) | Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47). | |
| UY32812A (es) | Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana. | |
| MX2012002927A (es) | Anticuerpos humanos de alta afinidad con el receptor activado por proteasa humana-2. | |
| MX2022009596A (es) | Anticuerpos anti-ror1 y composiciones. | |
| AR043616A1 (es) | Anticuerpos contra receptor humano il-21 y usos de los mismos | |
| CY1114271T1 (el) | Αντισωματα εξουδετερωσης, ανθρωπινου κυτταρομεγαλοϊου και χρηση αυτων | |
| MX2023008327A (es) | Anticuerpos inmunomoduladores de anticuerpo-farmaco. | |
| CR20200463A (es) | Anticuerpos | |
| CO2020006855A2 (es) | Composiciones y métodos para el agotamiento de células cd2+ | |
| ECSP23088752A (es) | Anticuerpos anti-adgre2 y usos de los mismos | |
| MX2024004447A (es) | Anticuerpos dirigidos a ccr2. | |
| MX2022003668A (es) | Metodos y composiciones para el tratamiento de la retinopatia diabetica. | |
| CL2024001326A1 (es) | Terapia combinada de inhibidores de cd73 e inhibidores de los receptores de adenosina a2a/a2b. | |
| MX2025009913A (es) | Anticuerpos anti-cd3 y metodos para su uso | |
| MX2024004652A (es) | Pautas posologicas para la movilizacion de celulas madre y progenitoras hematopoyeticas. | |
| MX2025007229A (es) | Tratamiento de la enfermedad autoinmunitaria |